ENBREL Dosing and Administration

Dosing Guidelines for Adult Patients1

For adult patients with moderate to severe rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, the recommended dose of ENBREL is 50 mg weekly.

MTX, glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs), or analgesics may be continued during treatment with ENBREL.

Based on a study of 50 mg ENBREL twice weekly in patients with RA that suggested higher incidence of adverse reactions but similar ACR response rates, doses higher than 50 mg per week are not recommended.

Dosing Guidelines for Patients with Moderately to Severely Active Juvenile Idiopathic Arthritis

63 kg (138 pounds) or more 50 mg weekly
Less than 63 kg (138 pounds) 0.8 mg/kg weekly

In JIA patients, glucocorticoids, NSAIDs, or analgesics may be continued during treatment with ENBREL. Higher doses of ENBREL have not been studied in pediatric patients.

The Flexibility of Multiple Self-Administration Options

Help your patients find a method that works for them. Step-by-step demonstrations are available for all 4 options. A copy of the Instructions for Use can be downloaded here.

Patients should receive injection training from their health care professional prior to self-administration.

Enbrel® SureClick® 50 mg/mL Autoinjector

Watch now
Patients can inject ENBREL using a 50-mg/mL prefilled autoinjector. The Enbrel® SureClick® autoinjector is for a single use only.

ENBREL Single-Use Prefilled Syringe

Watch now
Patients can inject ENBREL using a prefilled syringe available in 50-mg/mL and 25-mg/0.5-mL dosage strengths. The prefilled syringe is for a single use only.

ENBREL 25-mg Multi-Use Vial Free-hand Method

Watch now
For some children with JIA, one vial of ENBREL solution can be used for more than one dose. The free-hand method should be used for these children. The vial adapter method should not be used if the patient will be using the vial more than once.

ENBREL 25-mg Vial Adapter Method

Watch now
Patients who use a single vial of ENBREL for each dose may use the vial adapter device to assist with mixing and withdrawing ENBREL.

ENBREL should not be administered to patients with sepsis.1

Storing ENBREL1

For convenience, the ENBREL syringe, autoinjector, and dose tray for the multi-use vial can be stored at room temperature between 68°-77°F (20°-25°C) for up to 14 days.

Storage guidelines

  • Patients should store ENBREL in the refrigerator (36°-46°F or 2°-8°C) as a standard practice.
  • ENBREL should not be returned to the refrigerator after it has reached room temperature.
  • Mixed ENBREL powder should be used right away, or can be kept in the refrigerator for up to 14 days.
  • ENBREL should be protected from light or physical damage. Do not shake.
  • Do not store ENBREL in extreme heat or cold. Do not freeze.

Circumstances in Which You May Consider Discontinuation of ENBREL Therapy for Your Patients

Serious infections, including patients with pneumonia, sinusitis, abscess, and herpes zoster1,2

ENBREL should be discontinued if a patient develops a serious infection or sepsis. Consider the risks and benefits carefully prior to initiation of therapy in patients with chronic or recurrent infection. Monitor patients closely for infections during and after treatment, including the possible development of tuberculosis (TB) in patients who tested negative for latent TB prior to therapy initiation.

Pregnancy or intent to breast-feed1

ENBREL should be used in pregnancy only if clearly needed. For nursing mothers, a decision should be made whether to discontinue nursing or to discontinue the drug. ENBREL is Pregnancy Category B.

Vaccinations, including yellow fever, BCG, rubella, polio, cholera, typhoid, and varicella1-3

When taking ENBREL, patients may receive concurrent vaccination, except for live vaccines. Patients with significant exposure to varicella virus should temporarily discontinue ENBREL therapy and be considered for prophylactic treatment.

Most PsA patients receiving ENBREL were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving ENBREL. The clinical significance of this is unknown. Patients receiving ENBREL may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving ENBREL.

Surgery, including dental surgery or hip replacement1,2

ENBREL therapy should be put on hold for patients who are scheduled for surgery. ENBREL can lower the ability of the immune system to fight infections. Patients should be closely monitored for the development of signs and symptoms of infection during and after surgery.

View ENBREL safety and tolerability data

Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations

In moderate to severe RA

ENBREL improved clinical signs and symptoms

View data

Patient support every day

Help your patients start and stay on ENBREL with help from dedicated nurses, online demos, and services to keep them on track.

View our everyday support
You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
E-mail this page to a colleague
Please correct the fields marked in red
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.

Send another e-mail
Return to enbrel.com/RheumPro

We're sorry.

This content is not available at this time.


The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Phil Mickelson: A PsA patient's perspective
Disease activity vs. structural progression in RA
Treating Moderately Active RA
Rapid, Sustained Efficacy of ENBREL
Improving Outcomes in Psoriatic Arthritis
Achieving Clinical Remission
Efficacy of ENBREL Monotherapy for RA
A look back at 15 years